Security Snapshot

Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) Institutional Ownership

CUSIP: 984241109

13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$8.61

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Shares outstanding
45,101,565
SEC-reported price per share
$8.61
Insider filing price
$8.61
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 984241109.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 2 to 0 between Q3 2025 and Q4 2025.
  • SEC-reported value moved from $78,346 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

984241109

Latest holder period

n/a

13F holders

13D/G owners

1

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
1
Security
YMAB
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 6.2% -11% $13,338,337 -$1,431,000 2,796,297 -9.7% Anders Hove 19 Aug 2025

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
30
Latest
n/a
Rows shown
1-25 of 30
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$78,346 $8.61 0
2025 Q3 16,393 $78,346 -$125,346,804 $6.66 2
2025 Q2 27,903,915 $125,848,990 -$3,989,579 $4.51 96
2025 Q1 28,806,277 $127,612,664 -$6,925,835 $4.43 102
2024 Q4 28,798,220 $225,491,854 -$942,932 $7.83 111
2024 Q3 25,737,929 $338,544,539 +$17,304,991 $13.15 105
2024 Q2 24,348,906 $294,136,627 +$14,837,664 $12.08 95
2024 Q1 22,993,565 $373,875,065 +$49,054,572 $16.26 94
2023 Q4 20,232,989 $137,987,136 +$5,157,820 $6.82 93
2023 Q3 19,680,958 $107,258,625 +$812,221 $5.45 98
2023 Q2 19,501,430 $132,412,962 +$4,779,033 $6.79 94
2023 Q1 19,046,672 $95,423,185 -$1,127,392 $5.01 84
2022 Q4 19,342,439 $94,388,828 -$55,189,832 $4.88 90
2022 Q3 23,585,540 $340,103,128 -$17,897,969 $14.42 95
2022 Q2 24,763,276 $374,657,143 -$7,577,417 $15.13 90
2022 Q1 25,303,485 $300,604,312 -$14,876,098 $11.88 87
2021 Q4 25,735,284 $417,099,601 -$24,204,070 $16.21 94
2021 Q3 26,245,129 $749,015,343 -$2,981,846 $28.54 96
2021 Q2 26,145,321 $886,898,417 -$1,159,329 $33.80 99
2021 Q1 26,332,523 $796,209,961 +$116,007,549 $30.24 116
2020 Q4 22,809,127 $1,129,308,254 +$38,442,838 $49.51 115
2020 Q3 21,437,747 $823,089,252 +$3,018,102 $38.39 105
2020 Q2 21,284,113 $919,504,408 +$53,403,136 $43.20 108
2020 Q1 20,069,737 $522,452,562 +$16,002,866 $26.10 80
2019 Q4 19,404,437 $606,386,157 +$184,880,658 $31.25 81
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .